Unlearn Appoints Krates Ng as Chief Technology Officer to Lead Next Phase of Technological and Operational Expansion Unlearn®, a pioneer in developing artificial intelligence solutions to optimize clinical trials, has…
IBL International Partners with Grifols to Develop Cutting-Edge Biomarker Panels IBL International GmbH, a Tecan Group company renowned for its expertise in specialty diagnostics, has officially announced a strategic partnership…
New Cancer Cell Study Backs CEL-SCI’s Early Approval Bid for Multikine in Head & Neck Cancer CEL-SCI Corporation (NYSE American: CVM), a clinical-stage immunotherapy company developing innovative treatments for cancer…
Agitated Solutions Gets FDA IND Nod for Phase 3 Contrast Agent Trial Agitated Solutions, Incorporated (ASI), a medical technology company focused on cardiovascular imaging innovation, announced a pivotal regulatory milestone…
Guardian Pharmacy Services Expands LTC Reach with Naples Pharmacy Acquisition Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the largest and most forward-thinking long-term care (LTC) pharmacy providers in the…
Alpenglow Biosciences to Host AACR 2025 Dinner Talk on Spatial Biology in Endometrial Cancer Alpenglow Biosciences, a leading innovator in 3D spatial biology and digital pathology, is pleased to announce…
FDA Approves Opdivo Plus Yervoy® for Untreated MSI-H or dMMR Metastatic Colorectal Cancer Bristol Myers Squibb today announced a major milestone in cancer immunotherapy with the U.S. Food and Drug…
Ethris and Lonza Partner to Advance Spray-Dried mRNA Vaccines Targeting Respiratory Illnesses In a major step toward transforming the landscape of vaccine development and delivery, Ethris, a clinical-stage biotechnology company…
Avenacy Introduces Propofol Injectable Emulsion, USP to the U.S. Market Avenacy Launches FDA-Approved Propofol Injectable Emulsion, USP in the United States: A Milestone in Critical Care and Anesthesia Access Avenacy,…
Sail Biomedicines Welcomes Dr. Laura Sepp-Lorenzino to Its Board of Directors Sail Biomedicines, Inc., a pioneering biotechnology company at the forefront of programmable RNA-based medicines and a Flagship Pioneering-founded enterprise,…
Corcept Begins Trial of Relacorilant Combo in Resistant Ovarian Cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on the discovery and development of innovative therapies that modulate…
Kashiv BioSciences Obtains $150 Million in Debt Financing from GoldenTree Asset Management Kashiv BioSciences, LLC (“Kashiv” or “the Company”), a fully integrated and innovation-driven biopharmaceutical company, announced today the successful…